DIA Biosimilars 2013

Xoma

Boyle joins Bionovo

Friday, January 6, 2012 09:21 AM

Bionovo, a pharmaceutical company focusing on women’s health and cancer, has named David Boyle senior vice president and chief financial officer.

More... »

Cenduit: Now with Patient Reminders

XOMA, Aragen Bioscience collaborate

Wednesday, October 26, 2011 12:20 PM

XOMA and Aragen Bioscience have entered into an agreement under which Aragen Bioscience will provide its clients access to XOMA’s proprietary Human Engineering technology for antibody humanization. Financial terms were not disclosed.

More... »

CRF Health – eCOA Forum

XOMA 052 fails phase IIb

Tuesday, March 29, 2011 01:07 PM

California-based Xoma, focused on the discovery and development of therapeutic antibodies, said its phase IIb trial of Xoma 052 in type II diabetes patients did not achieve the primary endpoint of reduction in glycosylated hemoglobin, or HbA1c, after six monthly treatments with XOMA 052 compared to placebo. There were no serious drug-related adverse events.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs